Sugi Predict

Sugi Predict / Targets / CD274

CD274

Programmed cell death 1 ligand 1 · Q9NZQ7 · CD274 on Sugi Atlas →

147,921 patent compounds predicted against CD274, 83,194 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL358303 SCHEMBL358303 1.00 12/20
Bifenthrin Bifenthrin (SCHEMBL22467) 0.40 11/20
Bifenthrin Bifenthrin (SCHEMBL22468) 0.40 11/20
Bifenthrin Bifenthrin (SCHEMBL22469) 0.40 11/20
Bifenthrin Bifenthrin (SCHEMBL313858) 0.40 11/20
Bifenthrin Bifenthrin (SCHEMBL156820) 0.39 11/20
Bifenthrin Bifenthrin (SCHEMBL156821) 0.39 11/20
SCHEMBL407298 SCHEMBL407298 0.54 9/20
SCHEMBL178529 SCHEMBL178529 0.74 8/20
SCHEMBL310937 SCHEMBL310937 0.53 8/20
SCHEMBL373611 SCHEMBL373611 0.51 8/20
SCHEMBL373612 SCHEMBL373612 0.51 8/20
SCHEMBL373613 SCHEMBL373613 0.51 8/20
SCHEMBL137318 SCHEMBL137318 0.51 8/20
SCHEMBL280240 SCHEMBL280240 0.75 7/20
SCHEMBL200203 SCHEMBL200203 0.51 7/20
SCHEMBL200204 SCHEMBL200204 0.51 7/20
SCHEMBL400880 SCHEMBL400880 0.51 7/20
SCHEMBL426830 SCHEMBL426830 0.48 7/20
SCHEMBL410123 SCHEMBL410123 0.46 7/20

Clinical trials — most relevant to CD274 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria PHASE4RECRUITING
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) PHASE3COMPLETED
Effect of Tramadol Versus Morphine on PD1 and PD1-ligand in Patients With Chronic Cancer Pain PHASE2/PHASE3UNKNOWN
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) PHASE2ACTIVE_NOT_RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer PHASE2COMPLETED
Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma PHASE2COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Adelbelimab Combination Chemotherapy in Neoadjuvant Therapy for Squamous Cell Carcinoma of the Head and Neck PHASE2NOT_YET_RECRUITING
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007) PHASE2COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial PHASE2UNKNOWN
Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer PHASE2COMPLETED
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC PHASE2COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer PHASE1COMPLETED
A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma PHASE1COMPLETED
Phase I Biomarker Study (BMS-936558) PHASE1COMPLETED
A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors PHASE1COMPLETED
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC EARLY_PHASE1UNKNOWN
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Role of Programmed Death Ligand 1 in Colorectal Cancer nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CD274 binder may also engage these)

ProteinNameSimilarity
Q9EP73 — 0.996 Q9EP73 →
Q9UM44 — 0.992 Q9UM44 →
Q501W4 — 0.989 Q501W4 →
P04218 — 0.986 P04218 →
Q13740 — 0.985 Q13740 →
Q9JHJ8 — 0.985 Q9JHJ8 →
Q00609 — 0.985 Q00609 →
Q7Z7D3 — 0.985 Q7Z7D3 →
Q5RAL8 — 0.984 Q5RAL8 →
Q9BH13 — 0.984 Q9BH13 →
Q61490 — 0.983 Q61490 →
O35112 — 0.983 O35112 →
P42081 — 0.982 P42081 →
Q7TSP5 — 0.982 Q7TSP5 →
P97710 — 0.981 P97710 →
O46634 — 0.980 O46634 →
P42070 — 0.980 P42070 →
P42082 — 0.980 P42082 →
O54901 — 0.980 O54901 →
P42292 — 0.980 P42292 →
Q8K4F0 — 0.979 Q8K4F0 →
O95727 — 0.978 O95727 →
Q68EV1 — 0.978 Q68EV1 →
P16284 — 0.978 P16284 →
P51866 — 0.978 P51866 →
O46651 — 0.977 O46651 →
P41217 — 0.977 P41217 →
Q3SWT0 — 0.977 Q3SWT0 →
Q6DJ83 — 0.976 Q6DJ83 →
Q01638 — 0.976 Q01638 →